883 results on '"Kameda, H."'
Search Results
2. AB1037 CURRENT USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
3. POS0798 EFFICACY, SAFETY AND RADIOGRAPHIC OUTCOMES FROM THE PHASE 3 SELECT-AXIS 2 STUDY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: 2-YEAR DATA
4. AB1782-HPR USABILITY AND ACCEPTABILITY OF A NEW AUTOINJECTOR DEVICE AND ITS ASSOCIATED APP IN RHEUMATOLOGY PATIENTS
5. POS1122 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: ONE-YEAR RESULTS FROM A PHASE 3 STUDY
6. OP0128 PHARMACOKINETICS AND PHARMACODYNAMICS OF METHOTREXATE POLYGLUTAMATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH LOW OR HIGH DOSE-METHOTREXATE IN COMBINATION WITH ADALIMUMAB: RESULTS FROM THE MIRACLE TRIAL
7. Efficacité et tolérance d’upadacitinib chez des patients atteints de spondylarthrite ankylosante et ayant eu une intolérance et/ou un manque d’efficacité lors d’un traitement antérieur par biologique : analyse en sous-groupes
8. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy
9. IDF21-0079 The agreement between measured HbA1c and optimized target HbA1c based on the DASC-8 in older patients with diabetes
10. POS0299 EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION AND INFLAMMATION IN SACROILIAC JOINTS AND SPINE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR IMAGING OUTCOMES FROM A PHASE III RANDOMISED TRIAL
11. OP0062 EFFICACY AND SAFETY OF ADALIMUMAB WITH LOW AND HIGH DOSE-METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: THE RANDOMISED CONTROLLED MIRACLE STUDY
12. AB1523-HPR USABILITY AND ACCEPTABILITY OF A NEW AUTOINJECTOR DEVICE AND ITS ASSOCIATED APP IN AUSTRALIAN, FRENCH, GERMANY AND JAPANESE RHEUMATOLOGY PATIENTS
13. POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
14. AB0381 ULTRASONOGRAPHY TO PREDICT FLARE AFTER DISCONTINUATION OF BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REMISSION
15. Systemic lupus erythematosus complicated by cranial calcification: APLAR-0383
16. AB0253 COMPARISON OF PHARMACODYNAMICS OF METHOTREXATE AS METHOTREXATE-POLYGLUTAMATES CONCENTRATIONS IN RHEUMATOID ARTHRITIS; INTERIM DATA EVALUATION OF MIRACLE STUDY CONDUCTED IN JAPAN, KOREA AND TAIWAN
17. POS1396 DAMAGE PROGRESSION OF FINGER JOINT CARTILAGE EVALUATED BY ULTRASOUND AND X-RAY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
18. POS0925 EFFICACY OF SECUKINUMAB IN TNFI-NAÏVE PATIENTS ACROSS THE AXIAL SPONDYLOARTHRITIS SPECTRUM OVER 52 WEEKS: A POST HOC ANALYSIS OF THE MEASURE AND PREVENT CLINICAL TRIALS
19. Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters
20. Improvement of image quality on low-dose dynamic myocardial perfusion computed tomography with a novel 4-dimensional similarity filter
21. Le sécukinumab améliore les signes et symptômes de la spondyloarthrite axiale non radiographique : résultats d’une étude de phase III randomisée, contrôlée, stratifiée sur les signes objectifs d’inflammation à l’inclusion
22. JAK3 is involved in BAFF-mediated abnormal production of IL-6 by peripheral monocytes of patients with primary Sjögren’s syndrome: P081
23. AB1123 PROGRESSION OF FINGER JOINT CARTILAGE DAMAGE EVALUATED BY ULTRASOUND IN PATIENTS WITH RHEUMATOID ARTHRITIS
24. OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY
25. The addition of another disease-modifying anti-rheumatic drug, bucillamine, to methotrexate in place of infliximab improves the rate of infliximab-free sustained remission: 0147
26. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
27. Stochastic Simulation of Microseisms Using Theory of Conditional Random Fields
28. Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus
29. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population
30. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-α monoclonal antibody, infliximab
31. Mode Choice Model with Travel Time Reliability and Commuters' Travel Behavior Before/After a Major Public Transportation Service Closure
32. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor
33. Relationship between electrochemical properties of SOFC cathode and composition of oxide layer formed on metallic interconnects
34. Clinical characteristics related to methotrexate-induced pancytopenia
35. Conditional random fields containing non-stationary stochastic processes
36. Local current distribution in a ferromagnetic tunnel junction measured using conducting atomic force microscopy
37. Electroluminescence from InP-based Heterostructure Nanowires
38. SAT0257 A phase 2b/3 randomised, placebo-controlled, double-blind study of upadacitinib, a selective jak1 inhibitor, in japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic dmards
39. The linoleic acid metabolite, 13-HpODE augments the phosphorylation of EGF receptor and SHP-2 leading to their increased association
40. USABILITY AND ACCEPTABILITY OF A NEW AUTOINJECTOR DEVICE AND ITS ASSOCIATED APP IN RHEUMATOLOGY PATIENTS.
41. EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: ONE-YEAR RESULTS FROM A PHASE 3 STUDY.
42. PHARMACOKINETICS AND PHARMACODYNAMICS OF METHOTREXATE POLYGLUTAMATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH LOW OR HIGH DOSE-METHOTREXATE IN COMBINATION WITH ADALIMUMAB: RESULTS FROM THE MIRACLE TRIAL.
43. SAT0661 Finger joint cartilage thickness evaluated by ultrasound in patients with rheumatoid arthritis (RA)
44. THU0620 Persistence with biological disease-modifying antirheumatic drugs – a retrospective database study in japanese patients with rheumatoid arthritis
45. 147 A case of dermatomyositis with elevated serum kl-6 level associated with ovarian cancer
46. 182 Acute myositis as a flare manifestation of systemic lupus erythematosus
47. 375 Comparison of ultrasonographic joint and tendon involvements in hands between early, treatment-naïve patients with systemic lupus erythematosus and rheumatoid arthritis
48. Comparison of ultrasonographic joint and tendon findings in hands between early, treatment-naïve patients with systemic lupus erythematosus and rheumatoid arthritis
49. SAT0561 Finger Joint Cartilage Evaluated by Ultrasound and X-ray in Rheumatoid Arthritis and Control Joints
50. Low-temperature growth of InSb by vacuum MOCVD using TEln and SbH3
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.